No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
Glaukos Stock Down Despite NDA Submission of Epioxa to the FDA
Glaukos Insider Sold Shares Worth $1,502,800, According to a Recent SEC Filing
Glaukos Seeks FDA Approval for Non-Invasive Keratoconus Therapy Epioxa
Express News | Glaukos Submits New Drug Application to U.S. FDA for Epioxa™
The Three-year Returns Have Been Stellar for Glaukos (NYSE:GKOS) Shareholders Despite Underlying Losses Increasing
Is Glaukos (NYSE:GKOS) Weighed On By Its Debt Load?